# US 2024/0181085 A1 · Non-viral dna vectors and uses thereof for expressing pfic therapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0181085 A1
- Document ID: US20240181085A1
- Status: Published application
- Kind: A1
- Application number: 18/282,717
- Filed: 2022-03-18
- Published: 2024-06-06
- Earliest claimed: 2021-03-19
- Assignees: Generation Bio Co.
- Applicants: Generation Bio Co.
- Inventors: Ozan Alkan; Douglas Anthony Kerr; Leah Yu Liu; Phillip Samayoa; Nathaniel Silver
- Web page: https://patentgrep.com/patent/US20240181085A1

## CPC

- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C07K 14/435: from animals; from humans
- C07K 14/47: from mammals
- C12N 15/85: for animal cells
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/50: Vectors for producing vectors
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N 2830/60: from viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The application describes ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette encodes a transgene, e.g., selected from Table 1, encoding a PFIC therapeutic protein (e.g., ATP8B1, ABCB11, ABCB4 or TJP2). Some ceDNA vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable gene expression of PFIC therapeutic protein in vitro, exvivo and in vivo using the ceDNA vectors. Provided herein are method and compositions comprising ceDNA vectors useful for the expression of PFIC therapeutic protein in a cell, tissue or subject, and methods of treatment of diseases with said ceDNA vectors expressing PFIC therapeutic protein. Such PFIC therapeutic protein can be expressed for treating a subject with Progressive familial intrahepatic cholestasis (PFIC).

## Claims

### Claim 1

A capsid-free close-ended DNA (ceDNA) vector comprising:
at least one heterologous nucleotide sequence between flanking inverted terminal repeats (ITRs), wherein the at least one heterologous nucleotide sequence encodes at least one progressive familial intrahepatic cholestasis (PFIC) therapeutic protein.

### Claim 2 (depends on 1)

The ceDNA vector of claim 1, wherein the least one heterologous nucleotide sequence that encodes at least one PFIC therapeutic protein is selected from any of the sequences in Table 1.

### Claim 3 (depends on 1, 2)

The ceDNA vector of claim 1 or 2, wherein the ceDNA vector comprise a promoter selected from any of those in Table 7 operatively linked to the least one heterologous nucleotide sequence that encodes at least one PFIC therapeutic protein.

### Claim 4 (depends on 1, 2, 3)

The ceDNA vector of any of claims 1 to 3, wherein the ceDNA vector comprises an enhancer selected from any of those in Tables 8A-8C.

### Claim 5 (depends on 1, 2, 3, 4)

The ceDNA vector of any of claims 1 to 4, wherein the ceDNA vector comprises a 5′ UTR and/or intron sequence selected from any of those in Table 9A.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The ceDNA vector of any of claims 1 to 5, wherein the ceDNA vector comprises a 3′ UTR selected from any of those in Table 9B.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The ceDNA vector of any of claims 1 to 6, wherein the ceDNA vector comprises at least one poly A sequence selected from any of those in Table 10.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The ceDNA vector of any one of claims 1-7, wherein the ceDNA vector comprises at least one promoter operably linked to at least one heterologous nucleotide sequence.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The ceDNA vector of any one of claims 1-8, wherein the ceDNA vector is synthetically produced.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The ceDNA vector of any one of claims 1-9, wherein at least one ITR comprises a functional terminal resolution site and a Rep binding site.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The ceDNA vector of any one of claims 1-10, wherein one or both of the ITRs are from a virus selected from a parvovirus, a dependovirus, and an adeno-associated virus (AAV).

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The ceDNA vector of any one of claims 1-11, wherein the flanking ITRs are symmetric or asymmetric.

### Claim 13 (depends on 12)

The ceDNA vector of claim 12, wherein the flanking ITRs are symmetrical or substantially symmetrical.

### Claim 14 (depends on 12)

The ceDNA vector of claim 12, wherein the flanking ITRs are asymmetric.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The ceDNA vector of any one of claims 1-14, wherein one or both of the ITRs are wild type, or wherein both of the ITRs are wild-type.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The ceDNA vector of any one of claims 1-15, wherein the flanking ITRs are from different viral serotypes.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The ceDNA vector of any one of claims 1-16, wherein the flanking ITRs are from a pair of viral serotypes shown in Table 2.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The ceDNA vector of any one of claims 1-17, wherein one or both of the ITRs comprises a sequence selected from the sequences in Table 3.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The ceDNA vector of any one of claims 1-18, wherein at least one of the ITRs is altered from a wild-type AAV ITR sequence by a deletion, addition, or substitution that affects the overall three-dimensional conformation of the ITR.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The ceDNA vector of any one of claims 1-19, wherein one or both of the ITRs are derived from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The ceDNA vector of any one of claims 1-20, wherein one or both of the ITRs are synthetic.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The ceDNA vector of any one of claims 1-21, wherein one or both of the ITRs is not a wild type ITR, or wherein both of the ITRs are not wild-type.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The ceDNA vector of any one of claims 1-22, wherein one or both of the ITRs is modified by a deletion, insertion, and/or substitution in at least one of the ITR regions selected from A, A′, B, B′, C, C′, D, and D′.

### Claim 24 (depends on 23)

The ceDNA vector of claim 23, wherein the deletion, insertion, and/or substitution results in the deletion of all or part of a stem-loop structure normally formed by the A, A′, B, B′ C, or C′ regions.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The ceDNA vector of any one of claims 1-24, wherein one or both of the ITRs are modified by a deletion, insertion, and/or substitution that results in the deletion of all or part of a stem-loop structure normally formed by the B and B′ regions.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The ceDNA vector of any one of claims 1-24, wherein one or both of the ITRs are modified by a deletion, insertion, and/or substitution that results in the deletion of all or part of a stem-loop structure normally formed by the C and C′ regions.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The ceDNA vector of any one of claims 1-24, wherein one or both of the ITRs are modified by a deletion, insertion, and/or substitution that results in the deletion of part of a stem-loop structure normally formed by the B and B′ regions and/or part of a stem-loop structure normally formed by the C and C′ regions.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The ceDNA vector of any one of claims 1-27, wherein one or both of the ITRs comprise a single stem-loop structure in the region that normally comprises a first stem-loop structure formed by the B and B′ regions and a second stem-loop structure formed by the C and C′ regions.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The ceDNA vector of any one of claims 1-28, wherein one or both of the ITRs comprise a single stem and two loops in the region that normally comprises a first stem-loop structure formed by the B and B′ regions and a second stem-loop structure formed by the C and C′ regions.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The ceDNA vector of any one of claims 1-29, wherein one or both of the ITRs comprise a single stem and a single loop in the region that normally comprises a first stem-loop structure formed by the B and B′ regions and a second stem-loop structure formed by the C and C′ regions.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The ceDNA vector of any one of claims 1-30, wherein both ITRs are altered in a manner that results in an overall three-dimensional symmetry when the ITRs are inverted relative to each other.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The ceDNA vector of any one of claims 1-31, wherein one or both of the ITRs comprises a sequence selected from the sequences in Tables 3, 5A, 5B, and 6.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The ceDNA vector of any one of claims 1-32, wherein at least one heterologous nucleotide sequence is under the control of at least one regulatory switch.

### Claim 34 (depends on 33)

The ceDNA vector of claim 33, wherein at least one regulatory switch is selected from a binary regulatory switch, a small molecule regulatory switch, a passcode regulatory switch, a nucleic acid-based regulatory switch, a post-transcriptional regulatory switch, a radiation-controlled or ultrasound controlled regulatory switch, a hypoxia-mediated regulatory switch, an inflammatory response regulatory switch, a shear-activated regulatory switch, and a kill switch.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A method of expressing an PFIC therapeutic protein in a cell comprising contacting the cell with the ceDNA vector of any one of claims 1-34 for an amount of time sufficient for expression of the PFIC therapeutic protein.

### Claim 36 (depends on 35)

The method of claim 35, wherein the cell is a photoreceptor or a retinal pigment epithelium (RPE) cell.

### Claim 37 (depends on 35, 36)

The method of claim 35 or 36, wherein the cell in in vitro or in vivo.

### Claim 38 (depends on 35, 36, 37)

The method of any one of claims 35-37, wherein the ceDNA vector comprises at least one heterologous nucleotide sequence that is codon optimized for expression in the eukaryotic cell.

### Claim 39 (depends on 38)

The method of claim 38, wherein the at least one heterologous nucleotide sequence is selected from any in Table 1.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A method of treating a subject with Progressive familial intrahepatic cholestasis (PFIC), comprising administering to the subject a ceDNA vector of any one of claims 1-34, wherein at the ceDNA vector comprises least one heterologous nucleotide sequence encodes at least one PFIC therapeutic protein.

### Claim 41 (depends on 40)

The method of claim 40, wherein the least one heterologous nucleotide sequence that encodes at least one PFIC therapeutic protein is selected from any of the sequences in Table 1.

### Claim 42 (depends on 40, 41)

The method of claim 40 or 41, wherein the ceDNA vector is administered to a photoreceptor cell, or an RPE cell, or both.

### Claim 43 (depends on 40, 41, 42)

The method of any of claims 40 to 42, wherein the ceDNA vector expresses the PFIC therapeutic protein in a photoreceptor cell, or an RPE cell, or both.

### Claim 44 (depends on 40, 41, 42, 43)

The method of any of claims 40-43, wherein the ceDNA vector is administered by any one or more of: subretinal injection, suprachoroidal injection or intravitreal injection.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A pharmaceutical composition comprising the ceDNA vector of any one of claims 1-34.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A cell containing a ceDNA vector of any of claims 1-34.

### Claim 47 (depends on 46)

The cell of claim 46, wherein the cell a photoreceptor cell, or an RPE cell, or both.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A composition comprising a ceDNA vector of any of claims 1-34 and a lipid.

### Claim 49 (depends on 48)

The composition of claim 48, wherein the lipid is a lipid nanoparticle (LNP).

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 46, 48, 49)

A kit comprising the ceDNA vector of any one of claims 1-34 or the composition of claim 48 or 49 or the cell of claim 46.

### Claim 51

The ceDNA vector of any one of the previous claims, the ceDNA vector being obtained from a process comprising the steps of: (a) incubating a population of insect cells harboring a ceDNA expression construct in the presence of at least one Rep protein, wherein the ceDNA expression construct encodes the ceDNA vector, under conditions effective and for a time sufficient to induce production of the ceDNA vector within the insect cells; and (b) isolating the ceDNA vector from the insect cells.

### Claim 52 (depends on 51)

The ceDNA vector of claim 51, wherein the ceDNA expression construct is selected from a ceDNA plasmid, a ceDNA bacmid, and a ceDNA baculovirus.

### Claim 53 (depends on 51, 52)

The ceDNA vector of claim 51 or claim 52 wherein the insect cell expresses at least one Rep protein.

### Claim 54 (depends on 53)

The ceDNA vector of claim 53, wherein the at least one Rep protein is from a virus selected from a parvovirus, a dependovirus, and an adeno-associated virus (AAV).

### Claim 55 (depends on 54)

The ceDNA vector of claim 54, wherein the at least one Rep protein is from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A ceDNA expression construct that encodes the ceDNA vector of any one of claims 1-34.

### Claim 57 (depends on 56)

The ceDNA expression construct of claim 56, which is a ceDNA plasmid, ceDNA bacmid, or ceDNA baculovirus.

### Claim 58 (depends on 56, 57)

A host cell comprising the ceDNA expression construct of claim 56 or claim 57.
